Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FEMY Stock Forecast 2026-2027
$0.31
Current Price
$18.50M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to FEMY Price Targets
+3,816.4%
To High Target of $12.00
+3,163.7%
To Median Target of $10.00
+879.1%
To Low Target of $3.00
FEMY Price Momentum
-20.5%
1 Week Change
-31.1%
1 Month Change
-61.3%
1 Year Change
-46.6%
Year-to-Date Change
-72.4%
From 52W High of $1.11
+7.4%
From 52W Low of $0.29
📊 TOP ANALYST CALLS
Did FEMY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Femasys is one of their latest high-conviction picks.
Latest FEMY Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, FEMY has a bullish consensus with a median price target of $10.00 (ranging from $3.00 to $12.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $0.31, the median forecast implies a 3,163.7% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FEMY Analyst Ratings
3
Buy
0
Hold
0
Sell
FEMY Price Target Range
Low
$3.00
Average
$10.00
High
$12.00
Current: $0.31
Latest FEMY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FEMY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 3, 2026 | Lake Street | Benjamin Haynor | Buy | Initiates | $1.50 |
| Nov 20, 2025 | Laidlaw & Co. | Buy | Initiates | $N/A | |
| Aug 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 13, 2025 | Jones Trading | Buy | Maintains | $N/A | |
| May 9, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 19, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 27, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 13, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 14, 2024 | Chardan Capital | Buy | Maintains | $N/A |
Femasys Inc. (FEMY) Competitors
The following stocks are similar to Femasys based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Femasys Inc. (FEMY) Financial Data
Valuation Metrics
Market Cap
$18.50M
Enterprise Value
$21.39M
P/E Ratio
N/A
PEG Ratio
-1.2x
Price/Sales
9.4x
Growth & Margins
Revenue Growth (YoY)
+39.9%
Gross Margin
+62.7%
Operating Margin
-568.3%
Net Margin
+62.0%
EPS Growth
+24.5%
Financial Health
Cash/Price Ratio
+49.9%
Current Ratio
4.5x
Debt/Equity
80.0x
ROE
-455.8%
ROA
-66.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Femasys Inc. (FEMY) Business Model
About Femasys Inc.
What They Do
Develops innovative solutions for women's reproductive health.
Business Model
Femasys Inc. operates by providing minimally invasive, non-surgical technologies for women's reproductive health that can be administered in a physician's office. The company generates revenue through its diverse portfolio of products aimed at infertility treatment, diagnostic imaging, and gynecologic interventions, catering to both domestic and international healthcare providers.
Additional Information
Key products include FemaSeed for intratubal insemination, FemVue for ultrasound-based assessments, and FemCerv for cervical tissue sampling. The company is also developing FemBloc for non-surgical permanent birth control, emphasizing its commitment to addressing underserved areas in women's healthcare.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
51
CEO
Ms. Kathy Lee-Sepsick M.B.A.
Country
United States
IPO Year
2021
Website
femasys.comFemasys Inc. (FEMY) Latest News & Analysis
Latest News
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
24 days ago
Quick Summary
A new catheter has been introduced to complement FemVue®, enhancing in-office fertility evaluations. This development may impact fertility treatment offerings.
Why It Matters
The new catheter enhances FemVue®, potentially increasing market share and revenue in the fertility sector, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
29 days ago
Quick Summary
Femasys introduces FemaSeed® Complete to enhance early infertility care, allowing OB/GYNs to provide treatments within their practices amid declining fertility rates.
Why It Matters
Femasys' innovation in infertility care amidst declining fertility rates could boost demand for its services, potentially increasing revenue and market share, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Femasys Inc. (NASDAQ: FEMY) announced the first commercial use of its fertility portfolio in OB/GYN practices, featuring FemaSeed for infertility treatment, enhancing access to care.
Why It Matters
Femasys Inc.'s revenue-generating fertility portfolio signals growth potential, enhances in-office care efficiency, and may lead to increased market share in women's health, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
2 months ago
Quick Summary
Enrollment has begun in the FDA-authorized FINALE pivotal trial for FemBloc®, indicating progress towards U.S. approval.
Why It Matters
FDA authorization of the FINALE trial for FemBloc® signals progress in potential market entry, influencing future revenues and stock performance for involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Femasys Inc. (NASDAQ: FEMY) granted options to purchase 185,000 shares of common stock to two new non-executive employees, effective February 2026.
Why It Matters
Femasys granting stock options to new employees signals confidence in growth and aligns interests, potentially boosting company performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
3 months ago
Quick Summary
Femasys Inc. (NASDAQ: FEMY) announced approval of a new CPT code for its FemaSeed treatment, enhancing reimbursement strategy and potentially increasing adoption and access starting January 1, 2027.
Why It Matters
Approval of the new CPT code for FemaSeed enhances its reimbursement strategy, potentially increasing adoption and revenue for Femasys Inc., impacting investor sentiment positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FEMY Stock
What is Femasys Inc.'s (FEMY) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Femasys Inc. (FEMY) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $3.00.
Is FEMY stock a good investment in 2026?
According to current analyst ratings, FEMY has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FEMY stock?
Wall Street analysts predict FEMY stock could reach $10.00 in the next 12 months. This represents a 3,163.7% increase from the current price of $0.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Femasys Inc.'s business model?
Femasys Inc. operates by providing minimally invasive, non-surgical technologies for women's reproductive health that can be administered in a physician's office. The company generates revenue through its diverse portfolio of products aimed at infertility treatment, diagnostic imaging, and gynecologic interventions, catering to both domestic and international healthcare providers.
What is the highest forecasted price for FEMY Femasys Inc.?
The highest price target for FEMY is $12.00 from at , which represents a 3,816.4% increase from the current price of $0.31.
What is the lowest forecasted price for FEMY Femasys Inc.?
The lowest price target for FEMY is $3.00 from at , which represents a 879.1% increase from the current price of $0.31.
What is the overall FEMY consensus from analysts for Femasys Inc.?
The overall analyst consensus for FEMY is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are FEMY stock price projections?
Stock price projections, including those for Femasys Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 7:01 PM UTC